European Commission Approved Susvimo for Macular Degeneration
The refillable ocular implant replaces frequent eye injections for patients with neovascular age-related macular degeneration.
Updated on Sept. 21, 2026 in Biotech
Live Poll
Would you prefer a continuous medication implant over regular monthly eye injections for chronic eye conditions?
The European Commission has approved Susvimo, a refillable implant designed to deliver ranibizumab continuously for the treatment of neovascular age-related macular degeneration (nAMD). This regulatory milestone introduces an alternative to standard, frequent anti-VEGF eye injections for the approximately 1.7 million people living with the condition in the European Union.
Why it matters
Susvimo offers a long-term treatment pathway that reduces the patient burden associated with managing nAMD, a leading cause of vision loss. By requiring only two treatments per year, the implant aims to improve therapeutic adherence compared to traditional injection regimens.
The implant maintains vision for up to seven years in clinical observations. It operates at a concentration of 100 mg/mL of ranibizumab, requiring just two refills per year.
The players
Roche
A global healthcare giant focused on pharmaceuticals and diagnostics with a specialized portfolio in ophthalmology and drug delivery systems.
The details
The Contivue Port Delivery Platform uses a surgical, refillable implant that acts as a reservoir to deliver medication directly into the eye. This device allows for the continuous release of the drug, bypassing the need for repetitive intravitreal injections. The surgical procedure is conducted on an outpatient basis to place the device, which Roche is now exploring for use with additional therapeutic molecules.
Timeline
2025: Roche received a CE mark for the Contivue platform.
September 21, 2026: The European Commission approved Susvimo for nAMD.
The Tech Race
This approval validates the shift toward sustained-release ocular devices over conventional injection-based delivery models. The competition now centers on integrating new molecules into the Contivue platform to expand beyond current nAMD protocols.
Patients with nAMD may transition from monthly or bi-monthly clinical visits for injections to a twice-yearly maintenance schedule. Availability and specific rollout timelines for individual EU countries depend on national healthcare procurement and regulatory adoption.
The takeaway
The transition to device-based drug delivery signifies a shift in how chronic ocular conditions are managed long-term. Monitor national health agency bulletins across the European Union for specific clinic adoption timelines and patient eligibility criteria.
Further reading
For more developments in medical hardware, visit Biotech.
More information
View official company updates on the Roche corporate information portal.
Live Poll
Would you prefer a continuous medication implant over regular monthly eye injections for chronic eye conditions?
